title: A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate.
abstract: OBJECTIVE
  The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH).
  
  
  METHODS
  Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS).
  
  
  RESULTS
  Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 ± 6.9 vs. 10.7 ± 5.1, p = .8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 ± 6.8 vs. 3.3 ± 4.2, p = .02) than the OROS-MPH group.
  
  
  CONCLUSIONS
  Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment.
authors.affiliation: Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. tspencer@partners.org
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Spencer
authors.forename: Eric
authors.initials: E
authors.lastname: Mick
authors.forename: Craig B H
authors.initials: CB
authors.lastname: Surman
authors.forename: Paul
authors.initials: P
authors.lastname: Hammerness
authors.forename: Robert
authors.initials: R
authors.lastname: Doyle
authors.forename: Megan
authors.initials: M
authors.lastname: Aleardi
authors.forename: Meghan
authors.initials: M
authors.lastname: Kotarski
authors.forename: Courtney G
authors.initials: CG
authors.lastname: Williams
authors.forename: Joseph
authors.initials: J
authors.lastname: Biederman
mesh_terms: D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D057915:Drug Substitution; D005260:Female; D006801:Humans; D057194:Intention to Treat Analysis; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D008774:Methylphenidate